Gilead Sciences, Inc.
GILDHealthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.2%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
Follow GILD
Alert me
Gilead Sciences, Inc. (GILD) EV/Sales
As of Nov 19, 2026, Gilead Sciences, Inc. (GILD) trades at a EV/Sales of 7.3×. Over the past ten years it has ranged from 3.3× (June 2017) to 7.6× (November 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 4.1× and above the Healthcare sector median of 3.3×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.8× | 25.86% |
| FY2024 | 4.6× | 1.22% |
| FY2023 | 4.5× | (2.79%) |
| FY2022 | 4.7× | 13.31% |
| FY2021 | 4.1× | 3.20% |
| FY2020 | 4.0× | 6.84% |
| FY2019 | 3.7× | 3.92% |
| FY2018 | 3.6× | (11.08%) |
| FY2017 | 4.0× | 6.96% |
| FY2016 | 3.8× | (20.99%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 6.6× | 11.82% |
| Jun 2026 | 5.9× | (6.28%) |
| Mar 2026 | 6.3× | 9.29% |
| Dec 2025 | 5.8× | 7.95% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNY Sanofi compare | 2.1× |
| BMY Bristol Myers Squibb Company compare | 3.0× |
| PFE Pfizer Inc. compare | 3.2× |
| NVO Novo Nordisk A/S compare | 3.6× |
| AZN AstraZeneca PLC compare | 4.7× |
| MRK Merck & Co., Inc. compare | 5.5× |
| NVS Novartis AG compare | 5.6× |
| AMGN Amgen Inc. compare | 7.2× |
| GILD Gilead Sciences, Inc. | 7.3× |
| Drug Manufacturers General industry median | 4.1× |
| Healthcare sector median | 3.3× |
| Market median | 2.0× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement